Unitary pharmaceutical dosage form
AssigneeBristol-Myers Squibb & Gilead Sciences, LLC
InventorsTerrence C. Dahl, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLlYAI, Taiyin YANG
Life of this patent
Estimating the term…
Abstract
In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Claims30
A composition comprising tenofovir DF and a surfactant whereby the surfactant is in a stabilizing configuration with the tenofovir DF.
A method comprising preparing component 1 comprising tenofovir DF, preparing component 2 comprising efavirenz and a surfactant, and placing both components into stabilizing configuration with one another.
A product comprising emtricitabine, tenofovir DF and efavirenz, a surfactant, and a means for preventing destabilizing contact between the surfactant and tenofovir DF.
A composition comprising emtricitabine, tenofovir DF and efavirenz which is free of pharmaceutically unacceptable concentrations of FTU, mono-POC PMPA, dimer and mixed dimer.
A unitary dosage form comprising component 1 comprising tenofovir DF, and emtricitabine and component 2 comprising efavirenz and a surfactant, component 1 being spatially disposed in stabilizing configuration with component 2.
Dependencies are inferred from the claim text.